Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Cash & Equivalents (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of Cash & Equivalents data on record, last reported at $28.9 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 1.82% year-over-year to $28.9 million; the TTM value through Dec 2025 reached $28.9 million, up 1.82%, while the annual FY2025 figure was $28.9 million, 1.82% up from the prior year.
  • Cash & Equivalents reached $28.9 million in Q4 2025 per CLDX's latest filing, down from $36.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $115.1 million in Q1 2024 and bottomed at $17.1 million in Q1 2025.
  • Average Cash & Equivalents over 5 years is $39.6 million, with a median of $32.1 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: soared 297.69% in 2021, then plummeted 85.11% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $39.1 million in 2021, then decreased by 24.82% to $29.4 million in 2022, then increased by 18.3% to $34.8 million in 2023, then dropped by 18.55% to $28.4 million in 2024, then grew by 1.82% to $28.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $28.9 million in Q4 2025, $36.0 million in Q3 2025, and $23.0 million in Q2 2025.